211 related articles for article (PubMed ID: 479061)
1. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
[No Abstract] [Full Text] [Related]
2. High dosage tobramycin treatment of children with cystic fibrosis. Bacteriological effect and clinical ototoxicity.
Thomsen J; Friis B
Int J Pediatr Otorhinolaryngol; 1979 Jul; 1(1):33-40. PubMed ID: 553884
[TBL] [Abstract][Full Text] [Related]
3. Tobramycin dosing in cystic fibrosis.
Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
[No Abstract] [Full Text] [Related]
4. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
[No Abstract] [Full Text] [Related]
5. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
6. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
[TBL] [Abstract][Full Text] [Related]
7. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
[TBL] [Abstract][Full Text] [Related]
8. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
[No Abstract] [Full Text] [Related]
9. [Ochrobactrum anthropi bacteremia in a child with cystic fibrosis].
Yagüe-Muñoz A; Gregori-Roig P; Valls-López S; Pantoja-Martínez J
Enferm Infecc Microbiol Clin; 2010 Feb; 28(2):137-8. PubMed ID: 19811858
[No Abstract] [Full Text] [Related]
10. [Making antibiotic therapy easier to use. A welcome advance for those with cystic fibrosis].
Sabourin G
Perspect Infirm; 2011; 8(4):54-5. PubMed ID: 21812190
[No Abstract] [Full Text] [Related]
11. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.
Pedersen SS; Jensen T; Osterhammel D; Osterhammel P
Antimicrob Agents Chemother; 1987 Apr; 31(4):594-9. PubMed ID: 3606063
[TBL] [Abstract][Full Text] [Related]
12. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
McCrae WM; Raeburn JA; Hanson EJ
J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
[TBL] [Abstract][Full Text] [Related]
13. Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
Fitzpatrick SB; Rosenstein BJ
Clin Pediatr (Phila); 1983 Sep; 22(9):628-30. PubMed ID: 6224623
[TBL] [Abstract][Full Text] [Related]
14. [Pseudomonas infections in lungs of children born with cystic fibrosis. Effects and adverse effects during antibiotic therapy with tobramycin and carbenicillin].
Friis B; Thomsen J
Ugeskr Laeger; 1979 Jul; 141(29):1968-72. PubMed ID: 545764
[No Abstract] [Full Text] [Related]
15. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
Adeboyeku D; Jones AL; Hodson ME
J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
[TBL] [Abstract][Full Text] [Related]
16. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
[TBL] [Abstract][Full Text] [Related]
17. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
[TBL] [Abstract][Full Text] [Related]
18. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin.
Conway SP; Miller MG; Ramsden C; Littlewood JM
Acta Paediatr Scand; 1985 Jan; 74(1):107-13. PubMed ID: 3885674
[TBL] [Abstract][Full Text] [Related]
19. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
20. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
Prescott WA; Nagel JL
Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
